Skip to main
RNXT

RenovoRx (RNXT) Stock Forecast & Price Target

RenovoRx (RNXT) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

RenovoRx is taking positive steps towards further strengthening their position in the biopharmaceutical market. These include the recent appointment of a new CFO with successful experience in the industry, the commercialization efforts for its FDA-cleared medical device RenovoCath, and the positive results from the second interim analysis for its Phase III trial. With an increase in active commercial cancer centers and a promising pipeline, RenovoRx has a potential for strong revenue growth in the coming years. However, investors should also be aware of potential risks such as balance sheet and liquidity concerns, failure of product candidates, and changes in market sentiment. Nonetheless, RenovoRx presents a compelling opportunity for long-term growth in the biopharma sector with its innovative and targeted drug delivery platform and a large potential market for its products.

Bears say

RenovoRx is a clinical-stage biopharmaceutical company with a negative outlook due to several factors. Despite a large market potential and attractive current valuation, the company's induction phase is long and progress in their ongoing TIGeR-PaC study is slow. Additionally, the recent appointment of a new CFO may bring some stability, but there are still significant risks to achieving their share price target, including liquidity concerns, failure to demonstrate safety and efficacy in trials, and competition in the biotech industry.

RenovoRx (RNXT) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RenovoRx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RenovoRx (RNXT) Forecast

Analysts have given RenovoRx (RNXT) a Strong Buy based on their latest research and market trends.

According to 2 analysts, RenovoRx (RNXT) has a Strong Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RenovoRx (RNXT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.